200 related articles for article (PubMed ID: 23323461)
41. The role of tissue microarray in the era of target-based agents.
Franco R; Caraglia M; Facchini G; Abbruzzese A; Botti G
Expert Rev Anticancer Ther; 2011 Jun; 11(6):859-69. PubMed ID: 21707283
[TBL] [Abstract][Full Text] [Related]
42. [Genomic diagnosis in breast cancer practice].
Masuda S
Rinsho Byori; 2012 Oct; 60(10):969-74. PubMed ID: 23323462
[TBL] [Abstract][Full Text] [Related]
43. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
44. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
45. Enabling personalized cancer medicine through analysis of gene-expression patterns.
van't Veer LJ; Bernards R
Nature; 2008 Apr; 452(7187):564-70. PubMed ID: 18385730
[TBL] [Abstract][Full Text] [Related]
46. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
Saijo N
Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
[TBL] [Abstract][Full Text] [Related]
47. "Personalizing" therapy for non-small cell lung cancer.
D'Cunha J
Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
[TBL] [Abstract][Full Text] [Related]
48. Special report: pharmacogenomics of cancer-candidate genes.
Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(5):1-3. PubMed ID: 18080403
[No Abstract] [Full Text] [Related]
49. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.
Berz D; Wanebo H
J Surg Oncol; 2011 May; 103(6):574-86. PubMed ID: 21480252
[TBL] [Abstract][Full Text] [Related]
50. [Personalized therapy].
Hallek M; Wolf J
Internist (Berl); 2013 Feb; 54(2):145-6. PubMed ID: 23371256
[No Abstract] [Full Text] [Related]
51. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
52. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
53. MiRNAs as biomarkers and therapeutic targets in cancer.
Heneghan HM; Miller N; Kerin MJ
Curr Opin Pharmacol; 2010 Oct; 10(5):543-50. PubMed ID: 20541466
[TBL] [Abstract][Full Text] [Related]
54. Challenges for biomarkers in cancer detection.
Wagner PD; Verma M; Srivastava S
Ann N Y Acad Sci; 2004 Jun; 1022():9-16. PubMed ID: 15251933
[TBL] [Abstract][Full Text] [Related]
55. Molecular detection of gene mutations and methylation abnormalities: applications in solid tumor diagnosis.
Kraus A; Schuermann M
Expert Rev Mol Diagn; 2002 Mar; 2(2):97-108. PubMed ID: 11962346
[TBL] [Abstract][Full Text] [Related]
56. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
57. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies.
Ng T; Chan A
Crit Rev Oncol Hematol; 2012 Jan; 81(1):58-74. PubMed ID: 21429761
[TBL] [Abstract][Full Text] [Related]
58. Symposium on vindesine. Chairman's introductory remarks.
Freireich EJ
Cancer Treat Rev; 1980 Sep; 7 Suppl 1():1-4. PubMed ID: 7002297
[No Abstract] [Full Text] [Related]
59. Identifying cancer mutations as therapeutic targets.
Azvolinsky A
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122735
[No Abstract] [Full Text] [Related]
60. [Application of Mass Spectrometry to the Diagnosis of Cancer--Chairman's Introductory Remarks].
Yatomi Y
Rinsho Byori; 2015 Sep; 63(9):1080-1. PubMed ID: 26731897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
